Tennessee § 53-10-208 Source of products substituted - FDA approval required

Tennessee Statutes

§ 53-10-208 — Source of products substituted - FDA approval required

Tennessee § 53-10-208

Title53

This text of Tennessee § 53-10-208 (Source of products substituted - FDA approval required) is published on Counsel Stack Legal Research, covering Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tenn. Code Ann. § 53-10-208 (2026).

Text

(a)In making substitutions as allowed by this part, the pharmacist may use drugs and drug products manufactured within the territorial limits of any one (1) of the states of the United States, or of any other country, if the products have been approved by the federal food and drug administration (FDA), and have been given an "A" therapeutic equivalent rating by the FDA in the agency's publication, "Approved Drug Products with Therapeutic Equivalence Evaluations", also known as the "Orange Book". "A" rated drug products are those that the FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, including, but not limited to, drug products for which:

(1)There are no known or suspected bioequivalence problems and are designated "AA", "AN", "AO", "AP" or

Free access — add to your briefcase to read the full text and ask questions with AI

(a) In making substitutions as allowed by this part, the pharmacist may use drugs and drug products manufactured within the territorial limits of any one (1) of the states of the United States, or of any other country, if the products have been approved by the federal food and drug administration (FDA), and have been given an "A" therapeutic equivalent rating by the FDA in the agency's publication, "Approved Drug Products with Therapeutic Equivalence Evaluations", also known as the "Orange Book". "A" rated drug products are those that the FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, including, but not limited to, drug products for which: (1) There are no known or suspected bioequivalence problems and are designated "AA", "AN", "AO", "AP" or "AT", depending on the dosage form; or (2) Actual or potential bioequivalence problems have been resolved with adequate in vivo or in vitro evidence supporting bioequivalence and are designated "AB". (b) This section shall not apply to generic drugs and drug products that have not been rated. (c) For those drugs that have not been evaluated and rated for bioequivalency by the FDA, pharmacists are permitted to use their professional judgment in selecting a generic product for substitution.